Legendary Trader: “Buy These Three Stocks Before this September Event”

Luke Lango believes an event scheduled for mid-September is set to trigger a massive market shock, potentially defining the winners and losers for the rest of the year.  

Wed, September 11 at 8:00PM ET
 
 
 
 
Register Here
Healthcare Stocks Icon

Healthcare Stocks

Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.

The words "recession proof" written on a pink sticky note. bulletproof stocks

7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024

These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.

Interest rate and dividend concept. Businessman with percentage symbol and up arrow, Interest rates continue to increase, return on stocks and mutual funds, long term investment for retirement. Dividend stocks

7 Dependable Dividend Stocks for Long-Term Income

Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.

medicine research, pharmaceutical background, LJPC stock

3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct

These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.

Other industries you might be interested in

Icon depicting a DNA strand

Biotech

Marijuana leaf

Cannabis

Icon depicting pills

Psychedelics

Recent Healthcare Stocks Articles

3 Biotech Stocks With Key Catalysts Coming in December

By Ian Cooper, InvestorPlace Contributor
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

Why Is SciSparc (SPRC) Stock Up 47% Today?

By William White, InvestorPlace Writer
SciSparc stock is rising higher with heavy trading of SPRC shares as investors celebrate positive clinical trial results.

Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?

By William White, InvestorPlace Writer
Heart Test Laboratories stock is on the rise Wednesday as shares of HSCS see heavy trading without any clear news to report.

Unstoppable Giant: Why AMZN Stock Is the Growth Juggernaut to Own Forever

By David Moadel, InvestorPlace Contributor
It's hard to go wrong with AMZN stock as Amazon grows its market share in e-commerce, virtual healthcare, grocery delivery and other sectors.

3 Micro-Cap Stocks That Could Be Moonshots

By Matthew Farley, InvestorPlace Contributor
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.

It’s Time to Buy These 3 Dividend Aristocrats Trading Near 52-Week Lows

By Will Ashworth, InvestorPlace Contributor
Investing in Dividend Aristocrats is a good idea. Buying them when they’re near a 52-week low is even better.

3 Cannabis Stocks You’ll Regret Not Buying Soon: November 2023

By Ian Cooper, InvestorPlace Contributor
Cannabis stocks could see higher highs in 2024, especially with 70% of Americans now in strong favor of legalization.

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?

By William White, InvestorPlace Writer
Alaunos Therapeutics stock is on the rise Tuesday as TCRT investors react to a mixed earnings report for the third quarter of 2023.

3 Cutting-Edge Biotech Stocks for the Bold Investor

By Josh Enomoto, InvestorPlace Contributor
Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative…

Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.

By Rich Duprey, InvestorPlace Contributor
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks.

3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition

By Chris Markoch, InvestorPlace Contributor
After dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20.

9 Stocks to Buy Now After Democrats Sweep 2023 Elections

By Samuel O'Brient, InvestorPlace Reporter
The recent United States elections brought multiple victories for the Democratic Party. Here are the stocks to buy to profit.

3 Stocks to Buy for a Big Rally Backed by Improving Fundamentals

By Faisal Humayun, InvestorPlace Contributor
These are the stocks that are consistently improving and represent attractive businesses that are poised for accelerated growth.

Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?

By Josh Enomoto, InvestorPlace Contributor
Although Tenax Therapeutics has received a green light for its investigational drug, investors should exercise caution with TENX stock.

Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates

By Will Ashworth, InvestorPlace Contributor
Share repurchases have slowed in 2023, partly due to the 1% tax. Here are three buybacks partially paid for with debt offerings.

Why Is Tivic Health (TIVC) Stock Up 63% Today?

By William White, InvestorPlace Writer
Tivic Health stock is rising alongside with heavy trading of TIVC shares on Monday as investors prepare for its upcoming earnings report.

Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?

By William White, InvestorPlace Writer
TCON stock is falling on Monday as the company's shares give up their gains from an earnings rally on Friday.

Why Is Verve Therapeutics (VERV) Stock Down 39% Today?

By William White, InvestorPlace Writer
Verve Therapeutics stock is falling on Monday even after the company posted promising interim data from a Phase 1b clinical trial.
Load More Articles